Upfront

Transasia Bio-Medicals Signs MoU with Grifols, Spain

Grifols from Spain has signed an exclusive agreement with Transasia Bio-Medicals Ltd to distribute its range of instruments and reagents in the field of transfusion medicine for the Indian market. Hanne Matthews, Managing Director, Grifols Asia Pacific PTE Ltd, said, "The distribution partnership is a key element of our global growth strategy. We're working closely with partners to build strong customer relationships and broaden our presence in the rapidly-expanding diagnostics market."

"Through our relationship with Grifols, we are now in a position to offer our customers a complete portfolio of products in the transfusion medicine space," said Suresh Vazirani, Chairman & Managing Director of Transasia Bio-Medicals Ltd. "Working closely with Grifols will enable us to leverage their corporate strengths, while utilising our own market, customer development and service capabilities across the region. We expect this partnership to provide a significant boost to our blood transfusion business," he added.

The new line of products that Transasia would distribute would be WaDiana Compact, DG Spin, DG Therm in the instruments section, DG Gel cards and Grifols Red Blood Cells in the reagents section. DG Gel cards and Grifols Red Blood Cells which are based on gel test technology, are now becoming new serological standards for blood banks. Its flexible automation meets the needs for ABO & Rh typing, antibody screening and identification, compatibility testing, reverse serum grouping and antigen typing.

Grifols is a group of Spanish companies specialising in hospital pharmaceuticals sector, whose main purpose is to promote new health solutions for use in hospitals. The Group's activities are organised in three divisions—bioscience, hospital and diagnostic.

EH News Bureau